Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA ...

Officially unveiled at the American Society of Human Genetics (ASHG) 2025 meeting held in Boston, Genomics has launched Mystra, an AI-enabled human genetics platform designed to accelerate drug target ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single ...

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery ...

Respiratory infectious diseases, such as viral pneumonia, pose a serious threat to global public health. These diseases spread rapidly and widely, potentially causing severe complications such as ...

High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...